NEW YORK--(BUSINESS WIRE)--Neuro-Hitech, Inc. (NASDAQ: NHPI), a biopharmaceutical company focused on the development and commercialization of next-generation compounds against proven targets for neurodegenerative diseases, today announced that First Berlin Equity Research, a leading independent equity research firm, has initiated research coverage with a “Buy” rating and a price target of $10.00 per share.
